Ireland
--:--IST
Latest
Clinical Trials in Egypt / NCT03965988
Recruiting Phase 3

Docosahexaenoic Acid on Breath Holding Spells in Children

NCT03965988 · tracked via the Priya Life Science Egypt tracker
Phase
Phase 3
Started
2018-05-01
Last updated
2019-05-29

Condition(s) studied

Breath Holding Attack

Investigational drug(s) / intervention(s)

DHAPlacebo

DHA: Docosahexaenoic acid

Placebo: Placebo

Study summary

DHA on Breath Holding Spells

Eligibility

Sex
ALL
Min age
1 Month
Max age
5 Years
Healthy volunteers
No
Inclusion Criteria: * Children with newly diagnosed sprlls Exclusion Criteria Other treatment as iron and piracetam

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Sherief Abd-Elsalam Tanta Egypt Recruiting

More Sherief Abd-Elsalam trials in Egypt

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03965988 on ClinicalTrials.gov ↗ ← All trials in Egypt